{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicm6gwj2qpg3hmgvbwehexiomoocdbtpcngwblckzcreln53gkxlq",
    "uri": "at://did:plc:ghttxidrc2tjwtxvjizwwrej/app.bsky.feed.post/3mmfz3t7kyur2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihb5qiiwtcfdpv5drdxqeauxaflsr4rlughivtipqufyka27sy6qu"
    },
    "mimeType": "image/jpeg",
    "size": 107371
  },
  "path": "/2026/05/21/women-health-fda-abortion-flavored-vapes-marty-makary-polyendocrine-metabolic-ovarian-syndrome-mifepristone-midterm-elections/",
  "publishedAt": "2026-05-21T18:09:24.000Z",
  "site": "https://msmagazine.com",
  "tags": [
    "Health",
    "National",
    "Politics",
    "2026 Elections",
    "Abortion Access",
    "Donald Trump and the Trump Administration",
    "Sexual and Reproductive Health",
    "The Contrarian",
    "Women in Politics",
    "Women's Health",
    "Women’s Health Is a Democracy Issue—and a Midterm One",
    "Ms. Magazine"
  ],
  "textContent": "It is critically important to keep reproductive health _and_ the chaos at the Food and Drug Administration (FDA) front and center in the headlines. Why? Two words: midterm elections.\n\nLast week, within 48 hours of each other the Supreme Court issued an emergency stay pausing the Fifth Circuit’s attempt to let Louisiana negate the FDA rule that allows telehealth provision and mail delivery of mifepristone, _and_ FDA commissioner Marty Makary announced his immediate resignation after rumors that President Trump was planning to fire him.\n\nThough Makary’s antipathy toward deregulation of flavored vapes appears to have triggered his fall from grace, and the rest of the chaos is perhaps business as usual, the Trump administration’s tip-toe approach to mifepristone is the real story.\n\nThe Justice Department’s litigation approach seemingly has been to wait until October when the FDA’s so-called “safety review” is due—ordered despite the mountain of evidence proving mifepristone’s safety and efficacy. But reports indicate that study has not even begun and is mired in data delays caused by the Department of Health and Human Services.\n\nFoot-dragging? Finger-pointing? Old-fashioned incompetence? Who can tell anymore. But it surely hews to Republicans’ favor to keep the entire endeavor out of public sight, given that the vast majority (68 percent) of adults in this country oppose banning mifepristone.\n\nThe post Women’s Health Is a Democracy Issue—and a Midterm One appeared first on Ms. Magazine.",
  "title": "Women’s Health Is a Democracy Issue—and a Midterm One"
}